Answer
The terminal half-life in humans of alendronate, a component of Fosavance, is estimated to exceed ten years, reflecting its release from the skeleton.
Sources for this answer
- FOSAVANCE TabletsOrganon Pharma (UK) Limited · emc · SmPC §5.2 Pharmacokinetic properties · Version 25Document updated
Sources checked